INTRODUCTIONPersonalized/precision medicine requires the rapid, cost‐effective, and reliable tissue‐based assessment of clinically validated predictive biomarkers. In particular, modern thoracic oncology has deeply transformed the way in which we practice lung cytopathology. The initial perception that cytological samples were merely sufficient for a generic microscopic diagnosis of non‐small cell lung cancer (NSCLC) whereas molecular analysis could only be applied to formalin‐fixed paraffin‐embedded material now has been completely overcome. By coupling microscopy with biomarker characterization, cytology can guide targeted therapy for NSCLC. In individuals with locally advanced or metastatic disease, when patients are not surgical candidates, fine‐needle aspiration biopsy is an ideal minimally invasive approach to inform targeted lung cancer therapy decisions.The study by Guseva et al, published in this issue of Cancer Cytopathology, represents a step ahead to maximize the informativeness of cytological smears. Indeed, treatment paradigms for patients with advanced lung cancer are well established. If the epidermal growth factor receptor (EGFR) gene demonstrates an activating (sensitizing) mutation, the first‐generation tyrosine kinase inhibitors (TKIs) gefitinib (Iressa; AstraZeneca, Cambridge, United Kingdom) and erlotinib (Tarceva; Hoffmann‐La Roche, Basel, Switzerland) or the second‐generation TKI afatinib (Giotrif; Boehringer Ingelheim, Ingelheim, Germany) should be given as first‐line therapy. Similarly, the TKI crizotinib (Xalkori, Pfizer,
Cancer Cytopathology – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera